Physician profile
Randolph E Modlin
NPI 1942259114
$2,162.73
in general payments reported to CMS, 2019-2025
21 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $194 · 2021: $381 · 2022: $288 · 2023: $625 · 2024: $192 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,111.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.64 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $247.05 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $232.88 | 2019-2023 | Xarelto |
| Heartflow, INC. | $221.14 | 2023-2025 | Ffrct |
| Amgen INC. | $160.03 | 2019-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $143.25 | 2021-2023 | Brilinta, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $131.65 | 2022-2025 | Lifevest |
| Boston Scientific Corporation | $120.81 | 2022-2025 | General - Therapies |
| Pfizer INC. | $104.57 | 2019-2023 | |
| Esperion Therapeutics, INC. | $88.44 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $78.55 | 2023 | |
| Novo Nordisk INC | $72.04 | 2024-2025 | Wegovy, Ozempic |
| Impulse Dynamics (USA) INC. | $50.14 | 2023 | Optimizer |
| Sunovion Pharmaceuticals INC. | $39.09 | 2019 | |
| Lantheus Medical Imaging, INC. | $36.55 | 2023 | Definity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $34.66 | 2025 | Fluad, Flucelvax |
| Abbott Laboratories | $21.07 | 2024 | Jot Dx |
| Bayer Healthcare Pharmaceuticals INC. | $18.58 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.96 | 2021 | |
| Philips North America LLC | $13.59 | 2020 | |
| Medtronic Vascular, INC. | $13.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randolph Modlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.